Legend Biotech Reports Positive Early Data for Solid Tumor CAR-T (LB2102) and Strong CARVYKTI® Updates at ASCO
LEGN sits 64% above its 52-week low of $16.24 on light trading volume (0.3× avg).
Summary
Legend Biotech announced positive early clinical data for its solid tumor CAR-T therapy, LB2102, and presented new data reinforcing the strong profile of its approved multiple myeloma treatment, CARVYKTI®, at ASCO 2026.
Key Events · Product Development and Regulatory · LEGN
-
Positive Phase 1 Data for LB2102
First-in-human clinical data for LB2102, a DLL3-targeted CAR-T cell therapy for solid tumors (SCLC/LCNEC), showed an objective response rate of 28.6% and a disease control rate of 78.6% at higher dose levels, with a manageable safety profile in heavily pretreated patients.
-
CAR-T Expansion into Solid Tumors
These early results support the potential of CAR-T cell therapy in solid tumors, a challenging area, and represent a key pipeline expansion for Legend Biotech, following the announcement of this presentation on May 21, 2026.
-
Reinforced CARVYKTI® Efficacy and Safety
New analyses from the CARTITUDE program for CARVYKTI® (multiple myeloma) demonstrated sustained clinical benefit and a consistent safety profile, including 30-month overall survival rates greater than 85% in high-risk patients.
-
Novartis Collaboration
The LB2102 program is part of a license agreement with Novartis Pharma AG, which holds exclusive worldwide rights for development, manufacturing, and commercialization of DLL3-targeted CAR-T therapies.
Analysis · LEGN · Life Sciences
Legend Biotech presented encouraging first-in-human Phase 1 data for its investigational CAR-T therapy, LB2102, targeting solid tumors (SCLC/LCNEC). The data showed promising objective response and disease control rates with a manageable safety profile in heavily pretreated patients, marking a significant step in expanding CAR-T beyond blood cancers. Additionally, new analyses for their approved multiple myeloma therapy, CARVYKTI®, reinforced its durable efficacy and consistent safety, further solidifying its market position.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LEGN was trading at $26.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5B. The 52-week trading range was $16.24 to $45.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.